STOCK TITAN
  1. Home
  2. News
  3. ENVB

Enveric Biosciences, Inc. - ENVB STOCK NEWS

Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.

Enveric Biosciences, Inc. (ENVB) is a pioneering biotechnology company committed to the development of innovative neuroplastogenic small-molecule therapeutics aimed at treating mental health conditions such as depression, anxiety, and addiction disorders. Headquartered in the United States, Enveric is at the forefront of mental health research, with a focus on non-hallucinogenic solutions.

The company's flagship program, EB-003, represents a novel approach to tackling challenging mental health disorders. Unlike traditional treatments, EB-003 promotes neuroplasticity without causing hallucinations, providing a safer and potentially more effective option for patients.

Another key project in Enveric's pipeline is EB-002, previously known as EB-373. This next-generation synthetic prodrug of psilocin is being developed to offer new hope in the treatment of psychiatric disorders. With an emphasis on rigorous scientific research and clinical trials, Enveric strives to deliver breakthrough therapies that can significantly improve patients' quality of life.

Enveric's strategic vision includes forming partnerships and collaborations to enhance its research capabilities and accelerate the development of its therapeutic programs. Highlighting its commitment to innovation, the company is also investing in cutting-edge technologies such as artificial intelligence (AI) to further its research and development efforts.

Financially, Enveric Biosciences has been transparent about its funding efforts, ensuring that it maintains a robust financial foundation to support its research initiatives. With a strong commitment to ethical practices and patient-centric solutions, Enveric is emerging as a key player in the biotech sector, focused on addressing some of the most pressing mental health challenges of our time.

News

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Rhea-AI Summary
Enveric Biosciences (ENVB) has signed two non-binding term sheets with an undisclosed biotechnology company to potentially out-license cannabinoid-COX-2 conjugate compounds for joint disease treatment. The agreements could lead to milestone payments totaling up to $82 million, with royalty rates ranging from 0.25% to 10% on future sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.18%
Tags
none
-
News

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

Rhea-AI Summary
Enveric Biosciences (ENVB) secures patents for novel neuroplastogenic small-molecule therapeutics to treat depression, anxiety, and addiction disorders. The company obtains U.S. Patent No. 11,918,594 for 'Multi-Substituent Psilocybin Derivatives' and anticipates U.S. Patent No. 11,931,338 for 'Nitrilated Psilocybin Derivatives'. These patents enhance Enveric's patent portfolio, providing composition of matter claim coverage for potential drug candidates and compounds in their PsybraryTM collections. The patents also strengthen partnerships and licensing opportunities, showcasing the company's commitment to developing proprietary products for mental health disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
-
News

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

Rhea-AI Summary
Enveric Biosciences (ENVB) signs three non-binding term sheets with an undisclosed biotechnology company for out-licensing of compounds, potentially leading to $200 million in milestone payments. The agreements entail exclusive global licenses for drug development, with royalty rates up to 10% on future sales. Enveric's extensive library of novel molecules aims to address mental health conditions, showcasing the value of its proprietary drug discovery platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
74.49%
Tags
none
News

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Rhea-AI Summary
Enveric Biosciences (NASDAQ: ENVB) announces the sale of a cancer-related patent portfolio to focus on developing neuroplastogenic small-molecule therapeutics for mental health disorders. The company will invest in lead candidates EB-003 and EB-002, targeting depression, anxiety, and addiction disorders. Enveric plans to continue research and development in this area while providing foundational patent protection for the undisclosed purchasers of the divested portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.29%
Tags
none
-
News

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Rhea-AI Summary
Enveric Biosciences (ENVB) to initiate preclinical development of EB-003 in 2024 in preparation for IND submission
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
-
News

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market

Rhea-AI Summary
Enveric Biosciences (ENVB) announces agreements with holders of existing warrants to exercise at a reduced price, resulting in approximately $1.8 million in gross proceeds. The new warrants will allow for the purchase of up to 2,244,000 shares of common stock at an exercise price of $1.37 per share over a term of five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
none
News

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Rhea-AI Summary
Enveric Biosciences (ENVB) to initiate preclinical development of EB-003 in 2024 for IND submission
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.72%
Tags
none
-
News

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

Rhea-AI Summary
Enveric Biosciences (ENVB) Announces Positive Progress in GLP Safety and Toxicology Program for EB-373
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
clinical trial
-
News

Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”

Rhea-AI Summary
Enveric Biosciences (ENVB) to participate in Biotech Showcase 2024, presenting business and clinical development strategy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
News

Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Rhea-AI Summary
Enveric Biosciences (ENVB) has identified three novel neuroplastic compounds from its EVM301 Series with the potential to offer a first-in-class approach to address difficult-to-treat disorders by promoting neuroplasticity without inducing hallucinations. The company plans to select one of the compounds for preclinical development early in 2024 in anticipation of Investigational New Drug (IND) application for a first-in-human clinical trial. Enveric’s research team successfully narrowed the EVM301 Series to three candidates with preclinical data indicating 5HT2A receptor binding, induction of neuroplasticity, and positive stress recovery outcomes in animal models showing no indication of hallucinations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
none

FAQ

What is the current stock price of Enveric Biosciences (ENVB)?

The current stock price of Enveric Biosciences (ENVB) is $0.325 as of December 20, 2024.

What is the market cap of Enveric Biosciences (ENVB)?

The market cap of Enveric Biosciences (ENVB) is approximately 3.3M.

What does Enveric Biosciences specialize in?

Enveric Biosciences specializes in developing neuroplastogenic small-molecule therapeutics for treating depression, anxiety, and addiction disorders.

What is EB-003?

EB-003 is Enveric's lead program designed to promote neuroplasticity in treating mental health disorders without inducing hallucinations.

What is EB-002?

EB-002, formerly known as EB-373, is a next-generation synthetic prodrug of psilocin being developed for the treatment of psychiatric disorders.

Where is Enveric Biosciences headquartered?

Enveric Biosciences is headquartered in the United States.

How does Enveric Biosciences fund its research?

Enveric Biosciences maintains a robust financial foundation through transparent funding efforts to support its research initiatives.

Is Enveric involved in any partnerships or collaborations?

Yes, Enveric forms strategic partnerships and collaborations to enhance its research capabilities and accelerate its therapeutic programs.

How does Enveric ensure its treatments do not cause hallucinations?

Enveric focuses on non-hallucinogenic solutions, as evidenced by its lead program, EB-003, which promotes neuroplasticity without causing hallucinations.

What technologies is Enveric investing in?

Enveric is investing in cutting-edge technologies such as artificial intelligence (AI) to advance its research and development efforts.

What are the core values of Enveric Biosciences?

Enveric Biosciences is committed to ethical practices, patient-centric solutions, and innovative research to address mental health challenges.

Why is Enveric considered a key player in the biotech sector?

Enveric is emerging as a key player due to its pioneering approaches to mental health treatments and significant investments in innovative research.

Stock ENVB logo
Enveric Biosciences, Inc.

Nasdaq:ENVB

ENVB Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ENVB Stock Data

3.32M
9.59M
6.93%
7.06%
3.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NAPLES